Epidemiology, prevention and early detection of cervical cancer;Epidemiologie, Prävention und Früherkennung des Zervixkarzinoms

Onkologe

Volumn 22, Issue 10, 2016, Pages 725-736

  Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarker; Cervical cancer; Human papillomaviruses; Risk based management; Screening

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; COLPOSCOPY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; GENOTYPING TECHNIQUE; HUMAN; PRECANCER; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS;

EID: 84982994236     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-016-0092-7     Document Type: Article

References (46)

1. Gustafsson L, Ponten J, Zack M, Adami HO (1997) International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 8(5):755–763 (Sep)
2. zur Hausen H (2002) Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2(5):342–350 (May)
3. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE (2011) Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 103(5):368–383 (Mar)
4. Smith LM, Strumpf EC, Kaufman JS, Lofters A, Schwandt M, Levesque LE (2015) The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics 135(5):e1131–e1140
5. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM (2012) Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 1;206(11):1645–1651
6. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386
7. Jemal A, Bray F, Forman D, O’Brien M, Ferlay J, Center M, Parkin DM (2012) Cancer burden in Africa and opportunities for prevention. Cancer 118(18):4372–4384
8. Robert Koch Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (2013) Krebs in Deutschland 2009/2010. Berlin
9. Schiffman M, Wentzensen N (2013) Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev 22(4):553–560
10. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC (2008) Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: A retrospective cohort study. Lancet Oncol 9(5):425–434
11. Luhn P, Walker J, Schiffman M, Zuna RE, Dunn ST, Gold MA, Smith K, Mathews C, Allen RA, Zhang R, Wang S, Wentzensen N (2013) The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol 128(2):265–270
12. Guan P, Howell-Jones R, Li N, Bruni L, de SS, Franceschi S, Clifford GM (2012) Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 131(10):2349–2359
13. Brotherton JM, Jit M, Gravitt PE, Brisson M, Kreimer AR, Pai SI, Fakhry C, Monsonego J, Franceschi S (2016) Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. Int J Cancer 139(3):510–517
14. Panagiotou OA, Befano BL, Gonzalez P, Rodriguez AC, Herrero R, Schiller JT, Kreimer AR, Schiffman M, Hildesheim A, Wilcox AJ, Wacholder S (2015) Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: Long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ 351:h4358. doi:10.1136/bmj.h4358
15. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 298(7):743–753
16. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM, Gonzalez P, Jimenez S et al (2015) Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: Combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol 16(7):775–786
17. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT et al (2013) Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 8(7):e68329
18. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr., Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D et al (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365(17):1576–1585
19. Wentzensen N, Schiffman M (2014) Filling a gap in cervical cancer screening programmes. Lancet Oncol 15(3):249–251
20. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J (2012) Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30(Suppl 5):F88–F99
21. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J et al (2014) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383(9916):524–532
22. Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK (2014) Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 106(8):dju153–dju153
23. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr. et al (2012) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62(3):147–172
24. Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, Voorhorst F, Belien JA, Babovic M, Snijders PJ, Meijer CJ (2010) HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 340:c1040–c1040
25. Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, Prendiville WJ (2013) Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev 3:CD008054
26. Sahasrabuddhe VV, Luhn P, Wentzensen N (2011) Human papillomavirus and cervical cancer: Biomarkers for improved prevention efforts. Future Microbiol 6(9):1083–1098
27. Wentzensen N, Schiffman M, Palmer T, Arbyn M (2016) Triage of HPV positive women in cervical cancer screening. J Clin Virol 76(Suppl 1):S49–S55
28. Bergeron C, Giorgi-Rossi P, Cas F, Schiboni ML, Ghiringhello B, Dalla PP, Minucci D, Rosso S, Zorzi M, Naldoni C, Segnan N, Confortini M et al (2015) Informed cytology for triaging HPV-positive women: Substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst 107(2):dju423–dju423
29. Wentzensen N, Fetterman B, Castle PE, Schiffman M, Wood SN, Stiemerling E, Tokugawa D, Bodelon C, Poitras N, Lorey T, Kinney W (2015) p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. J Natl Cancer Inst 107(12):djv257
30. Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, Cadman L, Ashdown-Barr L, Costa MJ, Szarewski A (2014) Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J Clin Virol 60(1):44–49
31. Schiffman M, Burk RD, Boyle S, Raine-Bennett T, Katki HA, Gage JC, Wentzensen N, Kornegay JR, Aldrich C, Tam T, Erlich H, Apple R et al (2015) A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol 53(1):52–59
32. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N et al (2015) Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Gynecol Oncol 136(2):178–182
33. Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez R, Denton K, Hariri J, Keller T, von Knebel DM et al (2013) Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 105(20):1550–1557
34. Carozzi F, Gillio-Tos A, Confortini M, Del MA, Sani C, De ML, Girlando S, Rosso S, Naldoni C, Dalla PP, Zorzi M, Giorgi-Rossi P et al (2013) Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: A prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 14(2):168–176
35. De Strooper LMA, van Zummeren M, Steenbergen RDM, Bleeker MCG, Hesselink AT, Wisman GBA, Snijders PJF, Heideman DAM, Meijer CJLM (2014) CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol 67(12):1067–1071
36. Vasiljevic N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT (2014) Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol Oncol 132(3):709–714
37. Wentzensen N, Sherman ME, Schiffman M, Wang SS (2009) Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-science. Gynecol Oncol 112(2):293–299
38. Mirabello L, Sun C, Ghosh A, Rodriguez AC, Schiffman M, Wentzensen N, Hildesheim A, Herrero R, Wacholder S, Lorincz A, Burk RD (2012) Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 104(7):556–565
39. Vasiljevic N, Scibior-Bentkowska D, Brentnall A, Cuzick J, Lorincz A (2014) A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers. J Clin Virol 59(3):161–166
40. Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S, Shaber R, LaMere B, Clarke M, Lorincz AT, Castle PE, Schiffman M et al (2012) Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 104(22):1738–1749
41. Luhn P, Houldsworth J, Cahill L, Schiffman M, Castle PE, Zuna RE, Dunn ST, Gold MA, Walker J, Wentzensen N (2013) Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results. Gynecol Oncol 130(3):595–600
42. Bornstein J, Sideri M, Tatti S, Walker P, Prendiville W, Haefner HK (2012) 2011 terminology of the vulva of the International Federation for Cervical Pathology and Colposcopy. J Low Genit Tract Dis 16(3):290–295
43. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, Qiao YL (2004) Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 191(2):430–434 (Aug)
44. Wentzensen N, Walker J, Gold MA, Smith K, Zuna RE, Mathews C, Dunn ST, Zhang R, Moxley K, Bishop E, Tenney M, Nugent E et al (2012) Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol 33(1):83–89
45. Kelly RS, Walker P, Kitchener H, Moss SM (2012) Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities. BJOG 119(1):20–25
46. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH, Wilkinson EJ, Zaino RJ et al (2012) The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 16(3):205–242